Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888919 | 0.83 | HPGD (0.44) | SMN1; SMN2POLBGAAMEN1KMT2A | |
| SCHEMBL4879184 | 0.78 | KDM4E (0.51) | KMT2AALDH1A1L3MBTL1HPGDLMNA | |
| SCHEMBL4883127 | 0.78 | TSHR (0.62) | POLBGAAALDH1A1L3MBTL1 | |
| SCHEMBL4880034 | 0.78 | ALDH1A1 (0.47) | POLBGAAMEN1KMT2AMAPT | |
| SCHEMBL4883113 | 0.77 | HPGD (0.44) | SMN1; SMN2GAAKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL12284941 | 0.76 | SMN1; SMN2 (0.59) | SMN1; SMN2POLBGAAMEN1KMT2A | |
| SCHEMBL10780646 | 0.75 | SMN1; SMN2 (0.44) | SMN1; SMN2POLBGAAMEN1KMT2A | |
| SCHEMBL4883349 | 0.75 | CXCR2 (0.43) | SMN1; SMN2GAAMEN1KMT2AMAPT | |
| SCHEMBL27713876 | 0.74 | POLB (0.59) | SMN1; SMN2POLBGAAMEN1KMT2A | |
| SCHEMBL4889765 | 0.74 | CETP (0.49) | POLBGAAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789380-A1 | AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | Justus-Liebig-Universität Giessen (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006010362-A1 | AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2006-02-02 | — | — | WO | claimed |
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | SCHREINER PETER R | 2008-11-06 | — | — | US | disclosed |
| EP-1789380-A1 | AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | Justus-Liebig-Universität Giessen (DE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006010362-A1 | AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | GABRA5, GABRA1, GABRA4 | SMN1; SMN2 2166/4885POLB 2819/4885GAA 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.